The global pet diabetes care devices market size was valued at USD 2.56 billion in 2025 and is projected to grow from USD 2.71 billion in 2026 to USD 4.29 billion by 2034, registering a CAGR of 5.94% during the forecast period (2026–2034). North America dominated the pet diabetes care devices market with a market share of 48.95% in 2025.
Pet diabetes care devices are specialized medical tools used to monitor and manage diabetes in companion animals such as dogs and cats. These devices include blood glucose monitors, continuous glucose monitoring systems, insulin delivery pens, and testing supplies that help veterinarians and pet owners maintain optimal glucose levels. They support early diagnosis, regular monitoring, and effective disease management, improving treatment outcomes and enhancing the quality of life for diabetic pets.
The pet diabetes care devices market demand is increasing due to the rising prevalence of diabetes in pets, growing pet ownership, and increasing spending on animal healthcare. Continuous innovations, expanding veterinary services, and greater awareness are contributing to pet diabetes care devices market growth.
Download a Free Sample To learn more about this report,
The pet diabetes care devices market is moderately exposed to supply chain disruptions due to its reliance on electronic components, sensors, medical-grade plastics, and specialized manufacturing processes. Disruptions in global logistics, semiconductor availability, and raw material supplies can delay the production and distribution of glucose monitoring devices, insulin delivery systems, and testing accessories, affecting product availability across key markets. These challenges also increase manufacturing costs, extend lead times, and create inventory imbalances, influencing veterinary clinics, distributors, and pet owners worldwide. The market is demonstrating a capacity-constrained recovery, supported by improving component availability, diversified supplier networks, and expanding production capabilities that are gradually restoring supply stability and meeting growing demand.
A key market trend is the increasing adoption of continuous glucose monitoring devices for diabetic pets as veterinary care shifts toward real-time and less invasive disease management. Pet owners and veterinarians are moving from traditional intermittent blood glucose testing to wearable monitoring systems that provide continuous glucose insights, improving treatment accuracy and reducing stress for animals. This transition supports personalized insulin management, early detection of glucose fluctuations, and better long-term disease control. For example, Zoetis offers CGM solutions that enable veterinarians to monitor glucose levels in diabetic dogs and cats more efficiently.
The integration of pet diabetes care devices with digital health platforms enables remote monitoring and data sharing. Diabetes management is shifting from standalone devices to connected ecosystems that allow pet owners to track glucose readings, medication schedules, and health trends through mobile applications. This transition enhances treatment adherence, supports timely veterinary interventions, and improves overall disease management. For example, Abbott has expanded the use of its FreeStyle Libre technology in veterinary practice, allowing veterinarians to access continuous glucose data for improved diabetes management in pets.
The pet diabetes care devices market forecasts investments directed toward the development of continuous glucose monitoring systems, connected insulin delivery devices, and AI-enabled remote monitoring platforms for companion animals. Investment is also expected to support manufacturing expansion, product commercialization, veterinary digital health integration, and clinical validation of next-generation diabetes management technologies.
In June 2026, ALR Technologies SG Ltd. signed a Letter of Intent to acquire CGM Medical Technology Singapore Pte. Ltd. in a transaction valued at USD 45 million in cash plus 200 million ALR common shares. The strategic investment is intended to strengthen the manufacturing and commercialization of the GluCurve Pet CGM, expanding the company's presence in the veterinary continuous glucose monitoring market.
Growing Pet Humanization and Increasing Veterinary Adoption of Continuous Glucose Monitoring Drives Market
The increasing humanization of pets is driving demand for advanced diabetes care devices as owners invest more in preventive and chronic disease management. Pet owners increasingly prefer convenient home-monitoring technologies that improve treatment outcomes and simplify long-term care. This is accelerating adoption of connected glucose monitoring devices across veterinary practices.
The growing clinical adoption of continuous glucose monitoring systems in veterinary medicine is driving demand for pet diabetes care devices by replacing conventional intermittent blood glucose testing. CGM enables veterinarians to monitor glucose fluctuations over several days without repeated blood sampling, improving insulin dose adjustments and reducing stress in diabetic pets. This shift is increasing demand for wearable sensors, readers, and diabetes monitoring software.
Requirement for Specific Glucose Calibration and Low Diagnosis Rate of Diabetes in Companion Animals Restrain Market Expansion
Differences in glucose physiology between companion animals and humans restrain the adoption of pet diabetes care devices by increasing the need for species-specific calibration and validation. Many glucose monitoring technologies are originally designed for human use, requiring additional clinical validation before they can deliver reliable readings in dogs and cats. This limits regulatory approvals, slows the introduction of veterinary-specific devices, and reduces confidence among veterinarians in adopting newer monitoring technologies, thereby restraining market growth.
The low diagnosis rate of diabetes in companion animals restrains the demand for pet diabetes care devices by limiting the number of pets receiving long-term glucose monitoring and treatment. Many cases remain undiagnosed because early symptoms such as increased thirst, weight loss, and frequent urination are often mistaken for normal aging or other health conditions. This delays treatment initiation and reduces the adoption of glucose monitoring devices and insulin management solutions, particularly in developing veterinary markets.
Expansion of Veterinary Telemedicine and Development of Veterinary-Specific Continuous Glucose Monitoring Systems Offer Growth Opportunities to Market Players
The expansion of veterinary telemedicine is creating new opportunities for pet diabetes care device manufacturers by enabling remote glucose monitoring and digital disease management. Connected diabetes devices that automatically share glucose data with veterinarians support timely insulin adjustments without frequent clinic visits. For example, in 2025, Vetster expanded its telehealth platform across North America, increasing virtual chronic disease consultations, including diabetes management, creating greater demand for connected glucose monitoring devices integrated with remote veterinary care.
The growing development of continuous glucose monitoring systems designed specifically for companion animals presents a significant opportunity for market participants. Unlike adapted human devices, veterinary-specific CGMs improve glucose measurement accuracy, sensor retention, and treatment compliance, encouraging broader clinical adoption. According to the American Veterinary Medical Association, more than 65 million US households own a dog and over 46 million own a cat, providing a substantial addressable population for dedicated veterinary diabetes monitoring technologies as diabetes diagnoses continue to increase.
Difficulty in Maintaining Continuous Device Wearability and Limited Availability of Veterinary Diabetes Specialists Hinders Market Growth
Maintaining continuous wearability of diabetes monitoring devices remains a significant challenge, particularly in active dogs and cats. Companion animals frequently scratch, groom, swim, or engage in outdoor activities that can dislodge sensors before the intended monitoring period is completed. These interruptions reduce data continuity, require premature sensor replacement, and increase overall management complexity, creating challenges for both veterinarians and pet owners in achieving reliable long-term glucose monitoring.
Successful use of continuous glucose monitoring systems requires accurate interpretation of glucose trends, insulin adjustments, and long-term treatment planning. The shortage of trained specialists creates inconsistencies in device utilization and clinical decision-making, slowing the adoption of advanced diabetes care technologies across general veterinary practices.
The insulin delivery devices segment accounted for a share of 62.19%, owing to insulin pen adoption, precise dose administration, and compatibility with veterinary insulin formulations. These devices support controlled insulin delivery, reduce dosing errors, and improve long-term diabetes management in companion animals requiring regular insulin therapy.
The glucose monitoring devices segment is expected to grow at a CAGR of around 7.13% during the forecast period due to continuous glucose monitoring adoption, non-invasive sensor technologies, and demand for automated glucose data tracking. These devices enable real-time monitoring, improve insulin adjustment decisions, and support personalized diabetes management in companion animals.
In 2025, dogs accounted for a share of 54.36%, as canine diabetes management involves lifelong insulin therapy, routine glucose profiling, and higher adoption of veterinary monitoring protocols. These factors increase the use of insulin delivery devices and glucose monitoring solutions for diabetic dogs.
The cats segment is expected to grow at a CAGR of 6.47% during the forecast period, driven by increasing feline diabetes remission monitoring, obesity associated with metabolic disease management, and adoption of home-based glucose tracking. These factors encourage greater use of diabetes care devices for early detection and personalized treatment in diabetic cats.
The veterinary hospitals segment accounted for a share of 49.23% in 2025 due to in-clinic glucose curve assessment, access to veterinary diagnostic analyzers, and availability of trained professionals for insulin therapy optimization. These capabilities support accurate diabetes diagnosis, continuous monitoring, and advanced disease management for companion animals.
The homecare settings segment is expected to grow at a CAGR of 6.86% during the forecast period, driven by owner-operated glucose testing, reduced dependency on veterinary visits, and availability of compact monitoring devices. These solutions enable daily diabetes management at home, improve treatment adherence, and support routine glucose tracking for companion animals.
North America: Market Dominance Led by High Penetration of Companion Animal Insurance Coverage and Increasing Utilization of Reference Veterinary Laboratories
The North America pet diabetes care devices market accounted for the largest regional share of 48.95% in 2025, driven by advanced veterinary diagnostics infrastructure, increasing adoption of digital veterinary platforms, and high penetration of companion animal insurance coverage that improves access to chronic disease management solutions. According to the North American Pet Health Insurance Association, more than 7 million pets were insured in North America in 2024, supporting greater utilization of advanced veterinary monitoring technologies among pet owners.
The US pet diabetes care devices market was valued at USD 1.09 billion in 2025, driven by rapid adoption of continuous glucose monitoring systems in veterinary practices, a strong presence of specialty veterinary hospitals, and increasing availability of remote veterinary care platforms. According to the American Pet Products Association, more than 66% of US households owned a pet in 2025, creating a large consumer base for advanced diabetes management devices and home monitoring solutions for companion animals.
The pet diabetes care devices market in Canada was valued at USD 162.84 million in 2025, supported by the integration of diabetes management into provincial companion animal wellness programs, increasing utilization of reference veterinary laboratories for endocrine diagnostics, and growing demand for long-term monitoring solutions in aging pet populations. The country's strong emphasis on preventive veterinary medicine and coordinated chronic disease management is encouraging broader adoption of glucose monitoring devices and insulin delivery technologies across both urban and regional veterinary practices.
Asia Pacific: Fastest Growth Driven by Rising Establishment of Accredited Small Animal Referral Hospitals and Rising Integration of Smart Pet Healthcare Ecosystems
The Asia Pacific pet diabetes care devices market is expected to grow at a CAGR of 7.24% during the forecast period, showcasing the fastest regional growth. Growth is supported by expanding companion animal endocrinology services, increasing localization of veterinary diagnostic equipment manufacturing, and rising establishment of accredited small-animal referral hospitals. Growing investment in veterinary specialty infrastructure and improving accessibility of advanced diabetes diagnostics are accelerating the adoption of glucose monitoring and insulin delivery devices across emerging and developed markets in the region.
The China pet diabetes care devices market was valued at USD 146.07 million in 2025, driven by rapid expansion of urban pet medical chains, increasing domestic production of veterinary diagnostic technologies, and rising integration of smart pet healthcare ecosystems. The country's growing network of premium veterinary hospitals and digital pet health platforms is strengthening access to advanced diabetes diagnosis, long-term glucose monitoring, and technology-enabled chronic disease management for companion animals.
The India pet diabetes care devices market was valued at USD 74.72 million in 2025, fueled by expanding companion animal specialty clinics, increasing availability of veterinary endocrinology services in metropolitan cities, and growing demand for affordable point-of-care diabetes diagnostics. The expansion of organized veterinary networks such as Crown Veterinary Services, backed by Mars Veterinary Health to strengthen specialty care and clinical capabilities across major Indian cities, is improving access to advanced diabetes diagnosis and long-term disease management, supporting wider adoption of pet diabetes care devices.
The Japan pet diabetes care devices market was valued at USD 86.21 million in 2025, supported by rising adoption of advanced in-house veterinary analyzers, increasing utilization of feline-friendly clinical protocols for chronic disease management, and strong integration of periodic metabolic screening into companion animal wellness programs. The growing use of appointment-based preventive veterinary care and standardized diabetes follow-up protocols is accelerating demand for precision glucose monitoring and insulin delivery devices across companion animal practices.
The pet diabetes care devices market competitive landscape is moderately fragmented, with competition spread across established animal health companies, veterinary diagnostic providers, medical device manufacturers, and emerging digital veterinary technology firms. Leading players compete through advancements in continuous glucose monitoring accuracy, device reliability, veterinary validation, product availability, and strong relationships with veterinary clinics. Emerging players focus on developing species-specific monitoring solutions, connected health platforms, user-friendly devices, and partnerships with veterinary networks. The pet diabetes care devices market ecosystem is shaped by rising pet healthcare spending, increasing adoption of digital veterinary solutions, and growing demand for chronic disease management.
May 2026: ALR Technologies launched the GluCurve Pet CGM in Canada, making the veterinary specific continuous glucose monitoring system available for cats and dogs. The platform combines wearable CGM sensors and veterinary portal to support glucose monitoring and insulin management decisions.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Analyst
Pavan Warade is a Research Analyst with over 4 years of expertise in Technology and Aerospace & Defense markets. He delivers detailed market assessments, technology adoption studies, and strategic forecasts. Pavan’s work enables stakeholders to capitalize on innovation and stay competitive in high-tech and defense-related industries.
We are featured on:
sales@straitsresearch.com